Hamburg, June 2018Â –Â Since the groundbreaking discovery of human induced pluripotent stem cells (hiPSCs) by Shinya Yamanaka in 2006, the use of pluripotent stem cells (PSCs) has expeÂrienced a boom. Due to their extensive in vitro self-renewal properties and their ability to differentiate into many different cell types, PSCs, and especially hiPSCs, offer exciting promises in a wide range of cell appliÂcations including regenerative medicine. [Read more…]
Mesenchymal Stem Cells (MSCs)
Mesenchymal stem cells (MSCs) are a well-characterized population of adult stem cells that can differentiate into a variety of cell types (chondrocytes, osteoblasts, adipocytes, myocytes, and more).
Cynata Reports Positive 28-day Data from Cohort B of Phase 1 Trial of CYP-001 in GvHD
MELBOURNE, Australia, June 21, 2018 — Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX:CYP) is pleased to announce positive safety and efficacy data from a day 28 analysis of patients in Cohort B of its Phase 1 clinical trial of CYP-001, the Company’s lead Cymerus™ mesenchymal stem cell (MSC) product candidate, in steroid-resistant acute graft-versus-host disease (GvHD). [Read more…]
Global Radiation Threats Require Cutting-Edge Counter-Measures
Many governments, including the U.S. and Japan, are well aware of the dangers to their populations of exposure to high levels of radiation from nuclear accidents or dirty bomb attacks. Whereas Japan’s population was recently exposed at Fukushima following the tsunami of 2011, the U.S. Department of Defense has been stockpiling acute radiation syndrome (ARS) countermeasures as a precaution for many years. [Read more…]
RoosterBio Commercializes Industry’s First cGMP Human MSC Banks For Widespread Manufacturing
RoosterBio Launches Only Commercially-Available Working Cell Banks (WCBs) for Large-Scale hMSC Production
Frederick, MD, USA. January 24, 2018 –Â RoosterBio Inc., a leading manufacturer of adult, allogeneic human mesenchymal stem/stromal cells (hMSCs) and paired bioprocess media systems, continues to deliver on its mission to de-bottleneck and accelerate the Regenerative Medicine Industry by launching the only commercially-available working cell banks (WCBs) for large scale hMSC production. [Read more…]
Exciting Early Results in Cynata’s UK Trial of iPSC-Derived MSC Therapeutic Product
 Patients in Cohort A Respond Well, 1st Patient in Cohort B Dosed in Cynata’s CYP-001 Trial
Australian stem cell company, Cynata Therapeutics has released exciting early results from its ongoing clinical trial in the UK utilizing an iPS cell-derived mesenchymal stem cell (MSC) therapeutic product. [Read more…]
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- …
- 58
- Next Page »